The price of OTLK is predicted to go up 16.37%, based on the high correlation periods with SLF. The similarity of these two price pattern on the periods is 97.11%.
OTLK
SLF
Up: 16.37%Similarity: 97.11%
OTLK Revenue Forecast
OTLK EPS Forecast
OTLK FAQs
What is bull’s view on OTLK?
OTLK stock has bullish potential due to its oversold RSI (26.9) and recent 8.8% price recovery to $2.24, signaling a possible trend reversal. Analysts from Guggenheim and HC Wainwright maintain "Strong Buy" ratings with price targets of $12 and $30, respectively, driven by optimism around the European launch of ONS-5010 in 2025. Despite past setbacks, the stock's zero enterprise value and potential approval in Europe present significant upside.
What is bear's view on OTLK?
OTLK stock is currently trading at $2.045, down significantly from its 52-week high of $12.85. Bears argue that the stock's recent 72% decline over six months reflects weak fundamentals, including the failure of ONS-5010 to meet key FDA endpoints and reliance on uncertain European launches in 2025. Additionally, the company's financial health remains precarious, with limited cash flow and high dependency on external funding.
What is OTLK revenue forecast for next quarter?
The market consensus for OTLK's revenue in the upcoming quarter is projected to be approximately $702.6K USD.
BTIG lowered the firm's price target on Outlook Therapeutics to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did not surpass the 95% threshold for the primary endpoint in NORSE EIGHT despite the difference between ONS-5010 and ranibizumab falling within the pre-specified noninferiority margin at eight weeks. Despite NORSE EIGHT technically not meeting its primary endpoint, BTIG remains Buy rated. Outlook is now trading at a zero enterprise value, there is still a chance ONS-5010 could be approved, and the company is likely not getting any credit for ONS-5010's potential in Europe, where ONS-5010 is already approved and launch is expected to commence in 2025, the analyst tells investors in a research note.